Does heaven exist? With well over 100,000 plus recorded and described spiritual experiences collected over 15 years, to base the answer on, science can now categorically say yes. Furthermore, you can see the evidence for free on the website allaboutheaven.org.

Available on Amazon
also on all local Amazon sites, just change .com for the local version (.co.uk, .jp, .nl, .de, .fr etc.)


This book, which covers Visions and hallucinations, explains what causes them and summarises how many hallucinations have been caused by each event or activity. It also provides specific help with questions people have asked us, such as ‘Is my medication giving me hallucinations?’.

Available on Amazon
also on all local Amazon sites, just change .com for the local version (.co.uk, .jp, .nl, .de, .fr etc.)

Observations placeholder




Type of Spiritual Experience


Number of hallucinations: 4


A description of the experience

Dasatinib, previously known as BMS-354825, is a cancer drug sold under the trade name Sprycel. Dasatinib is an oral Bcr-Abl tyrosine kinase inhibitor (inhibits the "Philadelphia chromosome") and Src family tyrosine kinase inhibitor approved for first line use in patients with chronic myelogenous leukemia (CML)[1] and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). It is being evaluated for use in numerous other cancers, including advanced prostate cancer.

Adverse effects

Neutropenia and myelosuppression are common toxic effects. Fifteen patients (of 84, i.e. 18%) in one study developed pleural effusions, which were felt to be a side effect of dasatinib. Some of these patients required thoracentesis or pleurodesis to treat the effusions. Other adverse events include diarrhea, peripheral edema, and headache. Patients have developed abnormal liver function. Mild hypocalcemia was also noted.  Several cases of pulmonary arterial hypertension (PAH) have been found in patients treated with dasatinib

On October 11, 2011 the U.S. Food and Drug Administration (FDA) announced that dasatinib may increase the risk of a rare but serious condition in which there is abnormally high blood pressure in the arteries of the lungs (pulmonary hypertension, PAH). Symptoms of PAH may include shortness of breath, fatigue, and swelling of the body (such as the ankles and legs). In reported cases, patients developed PAH after starting dasatinib, including after more than one year of treatment.

Information about this risk has been added to the Warnings and Precautions section of the Sprycel drug label.

On Jan, 06, 2017   10,399 people reported to have side effects when taking Sprycel.
Among them, 4 people (0.04%) have Hallucination


On Jan, 31, 2016: 4,008 people reported to have side effects when taking Sprycel. Among them, 229 people (5.71%) have Death.

Time on Sprycel when people have Death  :

  < 1 month 1 - 6 months 6 - 12 months 1 - 2 years 2 - 5 years 5 - 10 years 10+ years
Death 29.17% 50.00% 8.33% 12.50% 0.00% 0.00% 0.00%

Gender of people who have Death when taking Sprycel  :

  Female Male
Death 34.74% 65.26%

Age of people who have Death when taking Sprycel  :

  0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+
Death 0.00% 0.00% 1.78% 2.37% 13.02% 20.12% 15.98% 46.75%



The source of the experience


Concepts, symbols and science items



Science Items

Activities and commonsteps